Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
After two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy. Increased evidence is demonstrating the efficacy of PD-L1/PD1 inhibition thera...
Guardado en:
Autores principales: | Wei-Bo Yu, Jian-Yu Rao |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KeAi Communications Co., Ltd.
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d9de201c2d614d868469c89bd5ca9cae |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Otgontuya Ganbaatar, et al.
Publicado: (2021) -
Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
por: Dina Mohamed El Samman, et al.
Publicado: (2021) -
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
por: Chia-Wei Li, et al.
Publicado: (2016) -
Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
por: Jang-June Park, et al.
Publicado: (2021) -
Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1 −/− mice
por: Jun T. Low, et al.
Publicado: (2021)